Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Next Previous
Trial Profile

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Expanded access; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 27 Oct 2016 Status changed from completed to recruiting.
    • 01 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 19 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top